AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26432693 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed patients in intervention and usual care practices
Number of subjects: 1204
Study 22020083 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 0
Study 22020083 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Number of subjects: 0
Study 22020083 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher parasitemias
Number of subjects: 0
Study 22020083 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemic children
Number of subjects: 0
Study 22708640 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg daily)
Number of subjects: 80
Study 22708640 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol succinate (50-100 mg daily)
Number of subjects: 80
Study 20056929 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation for acute stroke trials
Number of subjects: 28
Study 20056929 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Number of subjects: 28
Study 20056929 — intervention group
Group type: COMPARATOR
Intervention: Local presentation to the hub
Number of subjects: 28
Study 18051491 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of paracetamol as a single intravenous preemptive dose
Number of subjects: 50
Study 18051491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16268007 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle group (HL) - engaged in exercise for 12 weeks
Number of subjects: 30
Study 16268007 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 12161723 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg once daily for 5 days
Number of subjects: 421
Study 12161723 — intervention group
Group type: COMPARATOR
Intervention: Gemifloxacin 320 mg once daily for 7 days
Number of subjects: 421
Study 10554363 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic herniorrhaphy (LH)
Number of subjects: 123
Study 10554363 — intervention group
Group type: COMPARATOR
Intervention: Open herniorrhaphy (OH)
Number of subjects: 123
Study 7759701 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (Controlled Release, 200 mg once daily)
Number of subjects: 280
Study 7759701 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (Retard, 20 mg twice daily)
Number of subjects: 280
Study 2261152 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic
Number of subjects: 40
Study 2261152 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror tracing
Number of subjects: 40
Study 31130280 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15 measurement
Number of subjects: 208
Study 31130280 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried score
Number of subjects: 208
Study 31130280 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson index
Number of subjects: 208
Study 31130280 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15
Number of subjects: 208
Study 29486881 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical regenerative agent
Number of subjects: 19
Study 29486881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 26921460 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive antimicrobial photodynamic therapy (aPDT) with indocyanine green (ICG) + SRP
Number of subjects: 50
Study 26921460 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 50
Study 25568553 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethylstarch 130/0.4 (HES)
Number of subjects: 90
Study 25568553 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (1000 ml)
Number of subjects: 90
Study 25568553 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride 0.9% (1000 ml)
Number of subjects: 90
Study 22233204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (30 mg twice daily for 6 days)
Number of subjects: 0
Study 22233204 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (2 mg single dose)
Number of subjects: 0
Study 20434823 — intervention group
Group type: EXPERIMENTAL
Intervention: BIG Bone Injection Gun
Number of subjects: 40
Study 20434823 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ‐IO
Number of subjects: 40
Study 20434823 — intervention group
Group type: COMPARATOR
Intervention: Both devices
Number of subjects: 40
Study 18090299 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI-based HAART
Number of subjects: 650
Study 16120067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily for 5 days)
Number of subjects: 16
Study 16120067 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (30 mg once daily for 6 days)
Number of subjects: 16
Study 16120067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12131606 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5, 10, or 20 mg/kg
Number of subjects: 0
Study 12131606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9927022 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (4 months, 5 days/week, 40 minutes/session, mean HR 157 beats/min, EE 925±201 kJ)
Number of subjects: 74
Study 9927022 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 74
Study 9927022 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 74
Study 7779149 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam (2 x 20 mg on days 1 and 2)
Number of subjects: 16
Study 7779149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2186832 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3837
Study 2186832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study 87082 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral retinoid (Ro 10‐9359) and UVB radiation (Selective Ultraviolet Phototherapy=SUP)
Number of subjects: 23
Study 87082 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy only (control group)
Number of subjects: 23
Study 30187593 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving to Opportunity (MTO) trial rental subsidies redeemable in low-poverty neighborhoods plus housing counseling
Number of subjects: 3537
Study 30187593 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestricted Section 8 rental subsidies
Number of subjects: 3537
Study 30187593 — intervention group
Group type: COMPARATOR
Intervention: Public housing control
Number of subjects: 3537
Study 30187593 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving to Opportunity (MTO) trial
Number of subjects: 3537
Study 29254115 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Tape (KT)
Number of subjects: 31
Study 29254115 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 31
Study 29254115 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 31
Study 25828427 — intervention group
Group type: EXPERIMENTAL
Intervention: 1Hz rTMS
Number of subjects: 40
Study 25828427 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 40
Study 25828427 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor training (both groups)
Number of subjects: 40
Study 23333292 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone treatment for 12 weeks
Number of subjects: 360
Study 22153395 — intervention group
Group type: COMPARATOR
Intervention: Conventional hang-back technique
Number of subjects: 60
Study 22153395 — intervention group
Group type: EXPERIMENTAL
Intervention: Anchored hang-back technique
Number of subjects: 60
Study 19435390 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medications
Number of subjects: 0
Study 19435390 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 0
Study 19435390 — intervention group
Group type: COMPARATOR
Intervention: Atypical antipsychotics
Number of subjects: 0
Study 19435390 — intervention group
Group type: COMPARATOR
Intervention: Nonpharmacologic methods or other medications
Number of subjects: 0
Study 17349643 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 136
Study 17349643 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomic myomectomy
Number of subjects: 136
Study 14722734 — intervention group
Group type: EXPERIMENTAL
Intervention: ZD9331 in combination with cisplatin (100 mg/m2 and 50 mg/m2)
Number of subjects: 16
Study 14722734 — intervention group
Group type: EXPERIMENTAL
Intervention: ZD9331 in combination with cisplatin (130 mg/m2 and 50 mg/m2)
Number of subjects: 16
Study 14722734 — intervention group
Group type: EXPERIMENTAL
Intervention: ZD9331 in combination with cisplatin (130 mg/m2 and 75 mg/m2)
Number of subjects: 16
Study 14722734 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (ZD9331 and cisplatin)
Number of subjects: 16
Study 11289395 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2271
Study 9747868 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day for 5 years
Number of subjects: 13388
Study 9747868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13388
Study 7886750 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphamethrin-impregnated bed nets
Number of subjects: 0
Study 2893877 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation at a total dose over 2000 cGy (group I)
Number of subjects: 82
Study 2893877 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation at a total dose of 1800 cGy (group II)
Number of subjects: 82
Study 31658923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 100
Study 31658923 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid intervention integrating CPT with TBI psychoeducation and cognitive rehabilitation (SMART-CPT)
Number of subjects: 100
Study 31658923 — intervention group
Group type: COMPARATOR
Intervention: CPT and SMART-CPT (both interventions)
Number of subjects: 100
Study 29212368 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Laparoscopic Radical Prostatectomy (RALP)
Number of subjects: 3324
Study 29212368 — intervention group
Group type: COMPARATOR
Intervention: Open Radical Prostatectomy (ORP)
Number of subjects: 3324
Study 28629447 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation
Number of subjects: 0
Study 28629447 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation
Number of subjects: 0
Study 26037995 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal femoral nail antirotation (Group 1)
Number of subjects: 198
Study 26037995 — intervention group
Group type: COMPARATOR
Intervention: Dynamic hip screw (Group 2)
Number of subjects: 198
Study 23240729 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text messages (TM) for 12 weeks
Number of subjects: 20
Study 23240729 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TM)
Number of subjects: 20
Study 21596917 — intervention group
Group type: EXPERIMENTAL
Intervention: High NaCl intake (7.7 meq Na(+)/kg body wt per day)
Number of subjects: 8
Study 21596917 — intervention group
Group type: COMPARATOR
Intervention: Low NaCl intake (0.7 meq Na(+)/kg body wt per day)
Number of subjects: 8
Study 18427089 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced life-support (ALS) phase
Number of subjects: 2867
Study 18427089 — intervention group
Group type: COMPARATOR
Intervention: Basic life-support (BLS) phase
Number of subjects: 2867
Study 18427089 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced life-support (ALS) phase (specifically for patients with Glasgow Coma Scale score < 9)
Number of subjects: 2867
Study 18427089 — intervention group
Group type: COMPARATOR
Intervention: Basic life-support (BLS) phase (specifically for patients with Glasgow Coma Scale score < 9)
Number of subjects: 2867
Study 18427089 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced life-support (ALS) phase vs Basic life-support (BLS) phase
Number of subjects: 2867
Study 17298190 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial educational intervention by a pharmacist including disease information, drug therapy, diet education, and active telephone follow-up.
Number of subjects: 134
Study 17298190 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial educational intervention by a pharmacist.
Number of subjects: 134
Study 15561049 — intervention group
Group type: EXPERIMENTAL
Intervention: LVAD implantation
Number of subjects: 0
Study 15561049 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 0
Study 11741625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 17073
Study 11741625 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 17073
Study 9220319 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic low-dose dopamine (2 mg/kg/min) administered 1 hour before IL-2 and discontinued 6-12 hours after maximum IL-2 doses.
Number of subjects: 42
Study 9220319 — intervention group
Group type: COMPARATOR
Intervention: Standard supportive measures without dopamine (control group).
Number of subjects: 42
Study 9220319 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic low-dose dopamine (2 mg/kg/min).
Number of subjects: 42
Study 7698967 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein patch
Number of subjects: 84
Study 7698967 — intervention group
Group type: COMPARATOR
Intervention: PTFE patch
Number of subjects: 84
Study 2439856 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirically devised regimen of forceful spinal manipulation and injections of a dextrose‐glycerine‐phenol ('proliferant') solution
Number of subjects: 81
Study 2439856 — intervention group
Group type: COMPARATOR
Intervention: Parallel treatment with less extensive initial local anaesthesia and manipulation, and saline substitution for proliferant
Number of subjects: 81
Study 2439856 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue pain scores and pain diagrams
Number of subjects: 81
Study 28282777 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet
Number of subjects: 153
Study 28282777 — intervention group
Group type: COMPARATOR
Intervention: E-learning
Number of subjects: 153
Study 27582635 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminar on smoking-related diseases (3 hours) and training in respiratory diseases or thoracic surgery unit (at least 10 months)
Number of subjects: 150
Study 27582635 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group B)
Number of subjects: 150
Study 25268778 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive containing 20 mcg of ethinyl estradiol and 3 mg of drospirenone
Number of subjects: 56
Study 25268778 — intervention group
Group type: COMPARATOR
Intervention: Non-hormonal contraceptive methods
Number of subjects: 56
Study 24092689 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced breathing with I/E ratio 1:1 at 0.25 Hz
Number of subjects: 14
Study 24092689 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced breathing with I/E ratio 1:2 and 1:3 at 0.25 Hz
Number of subjects: 14
Study 24092689 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced breathing with I/E ratio 1:1, 1:2, and 1:3 at 0.1 Hz
Number of subjects: 14
Study 24092689 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced breathing with I/E ratio 1:1 at 0.1 Hz
Number of subjects: 14
Study 24092689 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced breathing with I/E ratio 1:1, 1:2, and 1:3 at 0.25 Hz
Number of subjects: 14
Study 21271128 — intervention group
Group type: EXPERIMENTAL
Intervention: Group GT (Threshold)
Number of subjects: 42
Study 21271128 — intervention group
Group type: EXPERIMENTAL
Intervention: Group GV (Voldyne)
Number of subjects: 42
Study 18809731 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (30 mg b.i.d.)
Number of subjects: 0
Study 18809731 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (100 mg/day)
Number of subjects: 0
Study 16468960 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus-MMF-prednisone
Number of subjects: 165
Study 16468960 — intervention group
Group type: COMPARATOR
Intervention: tacrolimus-MMF-prednisone
Number of subjects: 165
Study 12759471 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell trait (hemoglobin AS)
Number of subjects: 26
Study 9935203 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-3.A1 peptide (3 subcutaneous injections at monthly intervals)
Number of subjects: 39
Study 7726513 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam plus amikacin
Number of subjects: 706
Study 7726513 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime plus amikacin
Number of subjects: 706
Study 2719466 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg every 12 h for 3 days)
Number of subjects: 10
Study 2719466 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline (6 mg/kg by 30-min intravenous infusion)
Number of subjects: 10
Study 775615 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment
Number of subjects: 99
Study 775615 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 99
Study 31127607 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized FSH dose (100 IU/d for predicted hyper responders)
Number of subjects: 1032
Study 31127607 — intervention group
Group type: COMPARATOR
Intervention: Standard FSH dose (150 IU/d)
Number of subjects: 1032
Study 31127607 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized FSH dose (450, 225, or 100 IU/d based on AFC)
Number of subjects: 1032
Study 28778281 — intervention group
Group type: EXPERIMENTAL
Intervention: High progesterone levels on the day of hCG administration
Number of subjects: 40
Study 28778281 — intervention group
Group type: COMPARATOR
Intervention: Normal progesterone levels on the day of hCG administration
Number of subjects: 40
Study 25662406 — intervention group
Group type: EXPERIMENTAL
Intervention: KRM-20 (20 mg)
Number of subjects: 17
Study 25662406 — intervention group
Group type: EXPERIMENTAL
Intervention: KRM-20 (6 mg)
Number of subjects: 17
Study 25662406 — intervention group
Group type: EXPERIMENTAL
Intervention: KRM-20 (60 mg)
Number of subjects: 17
Study 25662406 — intervention group
Group type: EXPERIMENTAL
Intervention: KRM-20 (16 mg)
Number of subjects: 17
Study 25662406 — intervention group
Group type: EXPERIMENTAL
Intervention: KRM-20 (1.6 mg)
Number of subjects: 17
Study 23407209 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive journalism article about recovery from mental illness
Number of subjects: 0
Study 23407209 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative journalism article about dysfunctional public mental health system
Number of subjects: 0
Study 23407209 — intervention group
Group type: COMPARATOR
Intervention: Neutral journalism article about dental hygiene
Number of subjects: 0
Study 22428491 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS monitoring with the suggested algorithm (Group A)
Number of subjects: 253
Study 22428491 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS monitoring without the algorithm (Group B)
Number of subjects: 253
Study 22428491 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 253
Study 22428491 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 253
Study 19416257 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% methyl aminolaevulinate (MAL)
Number of subjects: 30
Study 19416257 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% methyl aminolaevulinate (MAL)
Number of subjects: 30
Study 19416257 — intervention group
Group type: COMPARATOR
Intervention: Both 16% and 8% MAL
Number of subjects: 30
Study 17572615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical corpectomy with preserved posterior vertebral wall (CPW)
Number of subjects: 178
Study 17572615 — intervention group
Group type: COMPARATOR
Intervention: Conventional corpectomy (CC)
Number of subjects: 178
Study 17572615 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CPW and CC
Number of subjects: 178
Study 15120768 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term group intervention combining informal multiprofessional teaching with facilitated peer exchange and support, delivered over 6 sessions of 90 minutes per week.
Number of subjects: 0
Study 15120768 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 0
Study 11267856 — intervention group
Group type: COMPARATOR
Intervention: Split-course irradiation (two courses of 20 Gy in five fractions of 4 Gy, separated by a rest of 2 weeks)
Number of subjects: 211
Study 11267856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) plus split-course irradiation (3-4 days before each of the two courses of radiotherapy, repeated every 3-4 weeks, for a total of six cycles)
Number of subjects: 211
Study 11267856 — intervention group
Group type: COMPARATOR
Intervention: Split-course irradiation
Number of subjects: 211
Study 11267856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) plus split-course irradiation
Number of subjects: 211
Study 9885179 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg acetylsalicylic acid (ASA)
Number of subjects: 42
Study 9885179 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg acetylsalicylic acid (ASA) + 2 x 200 mg dipyridamole
Number of subjects: 42
Study 9885179 — intervention group
Group type: COMPARATOR
Intervention: Phenprocoumon
Number of subjects: 42
Study 8279943 — intervention group
Group type: EXPERIMENTAL
Intervention: PAF antagonist Ro 24‐4736, 10 mg orally
Number of subjects: 10
Study 8279943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3569338 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mCi 131I
Number of subjects: 40
Study 3569338 — intervention group
Group type: COMPARATOR
Intervention: 30 mCi 131I
Number of subjects: 40
Study 3569338 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mCi 131I
Number of subjects: 40
Study 3569338 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mCi 131I (therapeutic dose for all patients)
Number of subjects: 40